Voglio sapere a riguardo di…

47310

Federal Register / Vol. 86, No. 161 / Tuesday, August 24, 2021 / Notices
FEDERAL RESERVE SYSTEM

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

lotter on DSK11XQN23PROD with NOTICES1

Notice of Proposals To Engage in or To Acquire Companies Engaged in Permissible Nonbanking Activities
Agency for Healthcare Research and Quality
The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act 12 U.S.C.
1843 BHC Act and Regulation Y, 12
CFR part 225 to engage de novo, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in 225.28 of Regulation Y
12 CFR 225.28 or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.
The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Banks indicated below and at the offices of the Board of Governors.
This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Boards Freedom of Information Office at https www.federalreserve.gov/foia/
request.htm. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.
Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 205510001, not later than September 8, 2021.
A. Federal Reserve Bank of Atlanta Erien O. Terry, Assistant Vice President 1000 Peachtree Street NE, Atlanta, Georgia 30309. Comments can also be sent electronically to Applications.Comments@atl.frb.org:
1. Peoples Bancshares, Inc., through its nonbank subsidiary, PB Community Impact Fund, LLC, both of Mendenhall, Mississippi; to engage de novo in community development activities pursuant to section 225.28b12 of the Boards Regulation Y.
Board of Governors of the Federal Reserve System, August 19, 2021.
Michele Taylor Fennell, Deputy Associate Secretary of the Board.
FR Doc. 202118198 Filed 82321; 8:45 am BILLING CODE 621001P

VerDate Sep<11>2014

16:43 Aug 23, 2021

Jkt 253001

Supplemental Evidence and Data Request on Schedule of Visits and Use of Telemedicine for Routine Antenatal Care Agency for Healthcare Research and Quality AHRQ, HHS.
ACTION: Request for supplemental evidence and data submissions.
AGENCY:

The Agency for Healthcare Research and Quality AHRQ is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review on Schedule of Visits and Use of Telemedicine for Routine Antenatal Care, which is currently being conducted by the AHRQs Evidencebased Practice Centers EPC Program.
Access to published and unpublished pertinent scientific information will improve the quality of this review.
DATES: Submission Deadline on or before September 23, 2021.
ADDRESSES:
Email submissions: epc@
ahrq.hhs.gov.
Print submissions:
Mailing Address: Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857.
Shipping Address FedEx, UPS, etc.:
Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville, MD
20857.
SUMMARY:

FOR FURTHER INFORMATION CONTACT:

Jenae Benns, Telephone: 3014271496
or Email: epc@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and Quality has commissioned the Evidence-based Practice Centers EPC
Program to complete a review of the evidence for Schedule of Visits and Use of Telemedicine for Routine Antenatal Care. AHRQ is conducting this technical brief pursuant to Section 902 of the Public Health Service Act, 42 U.S.C.
299a.
The EPC Program is dedicated to identifying as many studies as possible that are relevant to the questions for each of its reviews. In order to do so, we are supplementing the usual manual and electronic database searches of the
PO 00000

Frm 00030

Fmt 4703

Sfmt 4703

literature by requesting information from the public e.g., details of studies conducted. We are looking for studies that report on Schedule of Visits and Use of Telemedicine for Routine Antenatal Care, including those that describe adverse events. The entire research protocol is available online at:
https effectivehealthcare.ahrq.gov/
products/schedule-visits-antenatal-care/
protocol.
This is to notify the public that the EPC Program would find the following information on Schedule of Visits and Use of Telemedicine for Routine Antenatal Care helpful:
D A list of completed studies that your organization has sponsored for this indication. In the list, please indicate whether results are available on ClinicalTrials.gov along with the ClinicalTrials.gov trial number.
D For completed studies that do not have results on ClinicalTrials.gov, a summary, including the following elements: Study number, study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, primary and secondary outcomes, baseline characteristics, number of patients screened/eligible/enrolled/lost to follow-up/withdrawn/analyzed, effectiveness/efficacy, and safety results.
D A list of ongoing studies that your organization has sponsored for this indication. In the list, please provide the ClinicalTrials.gov trial number or, if the trial is not registered, the protocol for the study including a study number, the study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, and primary and secondary outcomes.
D Description of whether the above studies constitute ALL Phase II and above clinical trials sponsored by your organization for this indication and an index outlining the relevant information in each submitted file.
Your contribution is very beneficial to the Program. Materials submitted must be publicly available or able to be made public. Materials that are considered confidential; marketing materials; study types not included in the review; or information on indications not included in the review cannot be used by the EPC
Program. This is a voluntary request for information, and all costs for complying with this request must be borne by the submitter.
The draft of this review will be posted on AHRQs EPC Program website and available for public comment for a period of 4 weeks. If you would like to be notified when the draft is posted, please sign up for the email list at:

E:FRFM24AUN1.SGM

24AUN1